26.02.2022
The clinical observations of the article by Fabrizio Esposito, Harald Matthes and Friedemann Schad from the Havelhöhe Community Hospital in Berlin support the hypothesis that CRP is a possible therapeutic target in the treatment of early stages of severe COVID-19.
17.02.2022
A recently published article in the Journal of Clinical Medicine shows the influence of high levels of CRP on G-protein coupled receptors (GPCRs).
18.02.2022
The German magazine Superillu published an interview with an AMI patient who was treated with CRP apheresis and his physician.
20.01.22
At the web seminar "Biotech vs. SARS-CoV-2: A BioBilanz", Pentracor gave a lecture on CRP apheresis against COVID-19. The field report was presented by Managing Director Dr. Ahmed Sheriff.
12.02.2022
Pentracast is the name of our new, informative podcast in which various employees, users and many others answer questions from our medical device consultant Henrike Weß.
11.02.2022
Focus published an interview with an early COVID patient who was treated with CRP apheresis
18.01.2022
The article states that selective CRP apheresis could be an effective therapy option for COVID-19 patients with respiratory failure and greatly increased CRP levels, and that initial data from the German registry CACOV are encouraging.
Hennigsdorf, January 20, 2022 - The medical technology company Pentracor GmbH from Hennigsdorf (convertible bond ISIN: DE000A289XB9, WKN: A289XB) has employed Rainer Mohr as a new Chief Financial Officer (CFO) since January 1, 2022.
In this function, Rainer Mohr controls and implements the strategic development of the company in all commercial and financial areas in close coordination and cooperation with the management of Pentracor.
11.01.2022
The authors of the review article “Immune Mechanisms of Plaque Instability” from the Charité Cardiology Department describe the Pentracor CAMI-1 study “CRP apheresis in Acute Myocardial Infarction” as groundbreaking.
30.12.2021
"Most Viewed" article: A new case report from 7 patients suggests the effectiveness of CRP apheresis in severe COVID-19.
